問卷

TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Pediatrics

更新時間:2023-09-19

許雅淇
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

14Cases

2024-04-01 - 2028-08-03

Phase II

Active
xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
5Sites

Recruiting5Sites

2022-04-01 - 2024-03-25

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2018-08-01 - 2022-06-30

Others

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2021-02-01 - 2030-03-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-08-30 - 2027-06-17

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2022-10-11 - 2024-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2022-12-01 - 2025-08-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2018-06-01 - 2024-12-31

Phase III

Completed
A Phase III, Multiple-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of an Adjuvanted Inactivated Enterovirus 71 (EV71) Vaccine in Healthy Infants and Children
  • Condition/Disease

    Enterovirus 71 (EV71)

  • Test Drug

    nactivated EV71 whole viral particles adjuvanted with aluminum (Al(OH)3)

Participate Sites
7Sites

Terminated7Sites

2017-05-15 - 2019-05-31

Others

Immunogenicity and safety study of two formulations of GlaxoSmithKline (GSK) Biologicals’ human rotavirus (HRV) vaccine (444563), in healthy infants starting at age 6-12 weeks.
  • Condition/Disease

    Active immunisation of infants against gastroenteritis (GE) due to rotavirus (RV).

  • Test Drug

    HRV PCV-free vaccine

Participate Sites
6Sites

Terminated6Sites

1 2